A practical reference on growth hormone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-02 and is reviewed periodically as new material appears.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
In Virus (2019), directed by Aashiq Abu, Kallingal played nurse Akhila, a character based on Lini Puthussery — the nurse who died treating Kerala's first patient in the 2018 Nipah virus outbreak. Lini Puthussery's husband, who attended a screening of the film, said that Kallingal's portrayal was faithful and delivered "a flawless performance as Lini". Kallingal co-produced the film with Aashiq Abu under their production banner OPM Cinemas. Sowmya Rajendran described her performance as "expressive". In the 2021 film Santhoshathinte Onnam Rahasyam, directed by Don Palathara, Kallingal played an entertainment journalist opposite Jitin Puthenchery. Baradwaj Rangan described her performance as "terrific". The film won her Best Actress at the Diorama International Film Festival. In 2023 she appeared in Neelavelicham, a horror drama co-produced with Aashiq Abu. In 2025, Kallingal starred in Theatre, written and directed by Sajin Baabu, playing Meera, a woman who has lived an isolated life on a coastal Kerala island alongside her elderly mother. The film explores the conflict between traditional belief and modern science. The film had its world premiere at the Eurasian Bridge International Film Festival in Yalta on 9 October 2025, before its theatrical release on 16 October 2025. The role was physically demanding; director Sajin Baabu noted that Kallingal spent several hours atop a coconut tree for a single scene and completed multiple retakes despite sustaining bruises.
While attending undergraduate school in Rochester, New York, in 1839, classmates Clarke and Morton apparently participated in ether frolics with some regularity. In January 1842, by now a medical student at Berkshire Medical College, Clarke administered ether to a Miss Hobbie, while Elijah Pope performed a dental extraction. In so doing, he became the first to administer an inhaled anesthetic to facilitate the performance of a surgical procedure. Clarke apparently thought little of his accomplishment, and chose neither to publish nor to pursue this technique any further. Indeed, this event is not even mentioned in Clarke's biography. Crawford W. Long was a physician and pharmacist practicing in Jefferson, Georgia in the mid-19th century. During his time as a student at the University of Pennsylvania School of Medicine in the late 1830s, he had observed and probably participated in the ether frolics that had become popular at that time. At these gatherings, Long observed that some participants experienced bumps and bruises, but afterward had no recall of what had happened. He postulated that diethyl ether produced pharmacologic effects similar to those of nitrous oxide. On 30 March 1842, he administered diethyl ether by inhalation to a man named James Venable, in order to remove a tumor from the man's neck. Long later removed a second tumor from Venable, again under ether anesthesia. He went on to employ ether as a general anesthetic for limb amputations and childbirth.
Looksmaxxing has been connected to incel sub-culture since its origins within it. Writing for The Conversation, senior lecturer and researcher Jamilla Rosdahl of the Australian College of Applied Psychology considers that the practice converts young men into incels, as a result of TikTok algorithms. On the popularity of looksmaxxing amongst young people overall, she wrote that "where young people feel like they can't control their environment, they may turn to trends such as looksmaxxing as something they can control", attributing several real-world problems such as an unstable economy and the increase in young men struggling to get into relationships. In some cases, men involved in the practice have reported benefits such as getting a girlfriend, as well as positive affirmation from their peers after improving their looks. Albeit such praise is invariably mixed with critique, which helps maintain a common outlook with less attractive members, who all feel subordinate to the masculine ideal. Several methods of looksmaxxing have been criticized by doctors and dismissed as misinformation, including mewing and bonesmashing. Regarding mewing, researchers have argued that evidence supporting any change in facial structure is lacking. Facial surgeons have criticized bonesmashing saying it includes the risk for fractures, facial misalignment, neurovascular injuries, facial deformity, and alterations in vision.
Sources: en.wikipedia.org
=== Second World War === The TA's war deployment plan envisioned the divisions being deployed, as equipment became available, in waves to reinforce the British Expeditionary Force (BEF) that had already been dispatched to Europe. The TA would join regular army divisions when they had completed their training. In 1938, it was envisaged that this would take at least eight months from mobilisation. In fact, with mobilisation in September 1939, the first three TA divisions arrived to take their places in the front line by February 1940: the 48th (South Midland) Division, 50th (Northumbrian) Division and 51st (Highland) Division. In April, they were joined by five more, 12th (Eastern) Division, 23rd (2nd Northumbrian) Division, 42nd (East Lancashire) Division, 44th (Home Counties) Division and the 46th Division, making eight of the thirteen British divisions deployed, although three, 12th, 23rd, and 46th, were deployed, minus much of their equipment, and dubbed 'labour divisions' to be used for infrastructure work. In practice, all of the divisions were heavily engaged in the fighting. The 42nd, 44th, and 48th took part in the stand on the River Escaut, The 50th, 42nd, and 46th were chosen for the final stand at the perimeter of Dunkirk, despite the 46th being one of the digging" divisions with few anti-tank guns and artillery pieces.
=== Xie === In contrast to the majority of other functional entities, xuè or xiě (血, "blood") is correlated with a physical form – the red liquid running in the blood vessels. Its concept is, nevertheless, defined by its functions: nourishing all parts and tissues of the body, safeguarding an adequate degree of moisture, and sustaining and soothing both consciousness and sleep. Typical symptoms of a lack of xiě (usually termed "blood vacuity" [血虚; xiě xū]) are described as: Pale-white or withered-yellow complexion, dizziness, flowery vision, palpitations, insomnia, numbness of the extremities; pale tongue; "fine" pulse.
== Therapeutic applications == Given the ability to knock down, in essence, any gene of interest, RNAi via siRNAs presents opportunities in both basic and applied biology. One of the biggest challenges to siRNA and RNAi-based therapeutics is intracellular delivery. siRNA also has weak stability and pharmacokinetic behavior. Delivery of siRNA via nanoparticles has shown promise. siRNA oligos in vivo are vulnerable to degradation by plasma and tissue endonucleases and exonucleases and have shown only mild effectiveness in localized delivery sites, such as the human eye. Delivering pure DNA to target organisms is challenging because its large size and structure prevent it from diffusing readily across membranes. siRNA oligos circumvent this problem due to their small size of 21–23 nucleotides. This allows delivery via nano-scale delivery vehicles called nanovectors. A good nanovector for siRNA delivery should protect siRNA from degradation, enrich siRNA in the target organ, and facilitate the cellular uptake of siRNA. The three main groups of siRNA nanovectors are: lipid based, non-lipid organic-based, and inorganic. Lipid based nanovectors are excellent for delivering siRNA to solid tumors, but other cancers may require different non-lipid based organic nanovectors such as cyclodextrin based nanoparticles. siRNAs delivered via lipid based nanoparticles have been shown to have therapeutic potential for central nervous system (CNS) disorders.
Sources: en.wikipedia.org
== Medical uses == The primary target for the development of FIAU was the treatment of chronic hepatitis B virus (HBV) infection. FIAU is a nucleoside analogue, meaning that the molecule is similar to the building blocks of deoxyribonucleic acid, DNA. Once it enters the body and it is phosphorylated by viral thymidine kinase the FIAU is activated. The FIAU will then be incorporated into the viral DNA while the virus is dividing. The virus will begin building a new DNA strand and use FIAU as a ‘building block’, but as it is an analogue and not a real nucleotide the DNA chain cannot be completed. FIAU was a potent inhibitor of HBV replication, thus resulting in a large decrease in serum HBV DNA levels. FIAU (and its parent drug FIAC) was also studied for the use in treating herpes simplex virus (HSV), varicella zoster virus (VZV), and cytomegalovirus (CMV). Nowadays FIAU is an important compound in the field of drug-induced liver injury research. FIAU, despite its early promise, was never put on the market and has never been available for medicinal use. In the initial clinical trials FIAU was a potent inhibitor of the HBV replication, as patients experienced a large decrease in serum HBV DNA levels. And in the high-dosed groups the HBV DNA was reduced by 70 to 95%. But even though the treatment was very promising, the antiviral effect was almost always temporary.
Nandrolone to trestolone, trenbolone, norboletone, and ethylestrenol: The most commonly employed human physiological specimen for detecting AAS usage is urine, although both blood and hair have been investigated for this purpose. The AAS, whether of endogenous or exogenous origin, are subject to extensive hepatic biotransformation by a variety of enzymatic pathways. The primary urinary metabolites may be detectable for up to 30 days after the last use, depending on the specific agent, dose and route of administration. A number of the drugs have common metabolic pathways, and their excretion profiles may overlap those of the endogenous steroids, making interpretation of testing results a significant challenge to the analytical chemist. Methods for detection of the substances or their excretion products in urine specimens usually involve gas chromatography–mass spectrometry or liquid chromatography-mass spectrometry.
Chromosome walking can be used for the purpose of cloning a gene. It does this by using the known gene’s markers that are closest and can therefore be used in techniques like isolating DNA sequences and aiding in the sequencing and cloning of the DNA of organisms. Chromosome walking is also useful when it comes to filling in the gaps that may be present in genomes by locating clones that overlap with a library clone end. This means that for chromosome walking to be carried out, it requires a clone library of a genomic format. This is why Vectorette PCR is one of the methods that can be used to create this library for chromosome walking to occur. Vectorette PCR comes in handy when it is necessary to obtain the regions that are both upstream and downstream and flank a sequence that is already known. By obtaining these regions, it provides the library of a genomic format that chromosome walking requires.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.